{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:49:26Z","timestamp":1789001366471,"version":"build-2803163510"},"reference-count":199,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.autrev.2026.104002","type":"journal-article","created":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T15:46:49Z","timestamp":1770565609000},"page":"104002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Autoimmunity in the era of immune checkpoint inhibitors: the evolving epidemiology of autoimmune diseases and the possible impact of COVID-19"],"prefix":"10.1016","volume":"25","author":[{"given":"Naim","family":"Mahroum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Elsalti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Alsharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Jabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abderrahman","family":"Ouban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.autrev.2026.104002_bb0005","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1084\/jem.194.6.769","article-title":"Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo","volume":"194","author":"Hawiger","year":"2001","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0010","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1084\/jem.165.2.302","article-title":"Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo","volume":"165","author":"Jenkins","year":"1987","journal-title":"J Exp Med"},{"issue":"6370","key":"10.1016\/j.autrev.2026.104002_bb0015","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/356607a0","article-title":"CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones","volume":"356","author":"Harding","year":"1992","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000213","article-title":"Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer","volume":"2","author":"Granier","year":"2017","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.autrev.2026.104002_bb0025","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.cell.2015.08.038","article-title":"Releasing the brakes on Cancer immunotherapy","volume":"162","author":"Littman","year":"2015","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.autrev.2026.104002_bb0030","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4049\/jimmunol.179.6.3831","article-title":"Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter","volume":"179","author":"Gibson","year":"2007","journal-title":"J Immunol"},{"issue":"7130","key":"10.1016\/j.autrev.2026.104002_bb0035","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nature05563","article-title":"Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.autrev.2026.104002_bb0040","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.autrev.2026.104002_bb0045","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1084\/jem.20130790","article-title":"RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance","volume":"211","author":"Xiao","year":"2014","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104002_bb0050","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J Exp Med"},{"issue":"6332","key":"10.1016\/j.autrev.2026.104002_bb0055","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"issue":"5238","key":"10.1016\/j.autrev.2026.104002_bb0060","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0065","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"issue":"5502","key":"10.1016\/j.autrev.2026.104002_bb0070","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"issue":"280","key":"10.1016\/j.autrev.2026.104002_bb0075","doi-asserted-by":"crossref","first-page":"280sr1","DOI":"10.1126\/scitranslmed.3010274","article-title":"On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation","volume":"7","author":"Lesokhin","year":"2015","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.autrev.2026.104002_bb0080","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1158\/0008-5472.CAN-13-2908","article-title":"PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8(+) T cells induced by melanoma vaccines","volume":"74","author":"Fourcade","year":"2014","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.autrev.2026.104002_bb0085","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1158\/0008-5472.CAN-16-0274","article-title":"Tim-3 expression on tumor-infiltrating PD-1(+)CD8(+) T cells correlates with poor clinical outcome in renal cell carcinoma","volume":"77","author":"Granier","year":"2017","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.autrev.2026.104002_bb0090","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/nm.2871","article-title":"Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion","volume":"18","author":"Rangachari","year":"2012","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.autrev.2026.104002_bb0095","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1128\/MCB.01983-06","article-title":"PAG-associated FynT regulates calcium signaling and promotes anergy in T lymphocytes","volume":"27","author":"Davidson","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.autrev.2026.104002_bb0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.coi.2017.01.001","article-title":"Immune checkpoint receptors in cancer: redundant by design?","volume":"45","author":"Li","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.autrev.2026.104002_bb0105","article-title":"An IL-27\/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction","volume":"6","author":"Zhu","year":"2015","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.autrev.2026.104002_bb0110","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1158\/2326-6066.CIR-14-0150","article-title":"Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells","volume":"3","author":"Kouo","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"13","key":"10.1016\/j.autrev.2026.104002_bb0115","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1158\/0008-5472.CAN-13-2690","article-title":"LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.autrev.2026.104002_bb0120","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/eji.200323382","article-title":"The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells","volume":"33","author":"Workman","year":"2003","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104002_bb0125","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/2326-6066.CIR-14-0072","article-title":"VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy","volume":"2","author":"Lines","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"10.1016\/j.autrev.2026.104002_bb0130","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1084\/jem.20100619","article-title":"VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses","volume":"208","author":"Wang","year":"2011","journal-title":"J Exp Med"},{"issue":"6127","key":"10.1016\/j.autrev.2026.104002_bb0135","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily--CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0140","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med"},{"issue":"5256","key":"10.1016\/j.autrev.2026.104002_bb0145","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.autrev.2026.104002_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00829","article-title":"Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models","volume":"8","author":"Decker","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0155","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.autrev.2026.104002_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02965","article-title":"The intriguing history of cancer immunotherapy","volume":"10","author":"Dobosz","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104002_bb0165","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3389\/fimmu.2018.01474","article-title":"Biomarkers for clinical benefit of immune checkpoint inhibitor treatment-a review from the melanoma perspective and beyond","volume":"9","author":"Buder-Bakhaya","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104002_bb0170","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/cam4.5067","article-title":"Immune checkpoint inhibitors as first line in advanced melanoma: evaluating progression-free survival based on reconstructed individual patient data","volume":"12","author":"Ossato","year":"2023","journal-title":"Cancer Med"},{"issue":"8","key":"10.1016\/j.autrev.2026.104002_bb0175","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.autrev.2026.104002_bb0180","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jaad.2020.03.131","article-title":"Immune checkpoint inhibitors to treat cutaneous malignancies","volume":"83","author":"Barrios","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104002_bb0185","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104002_bb0190","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2217\/imt-2021-0119","article-title":"Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma","volume":"13","author":"Tarhini","year":"2021","journal-title":"Immunotherapy"},{"issue":"19","key":"10.1016\/j.autrev.2026.104002_bb0195","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2026.104002_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/cells11030320","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects","volume":"11","author":"Tang","year":"2022","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.autrev.2026.104002_bb0205","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.autrev.2026.104002_bb0210","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2026.104002_bb0215","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"issue":"10064","key":"10.1016\/j.autrev.2026.104002_bb0220","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.autrev.2026.104002_bb0225","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4111\/icu.2018.59.5.285","article-title":"Immune checkpoint inhibitors for urothelial carcinoma","volume":"59","author":"Kim","year":"2018","journal-title":"Investig Clin Urol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0230","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104002_bb0235","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0240","doi-asserted-by":"crossref","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw"},{"issue":"12","key":"10.1016\/j.autrev.2026.104002_bb0245","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"22","key":"10.1016\/j.autrev.2026.104002_bb0250","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.autrev.2026.104002_bb0255","first-page":"560","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.autrev.2026.104002_bb0260","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.autrev.2026.104002_bb0265","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104002_bb0270","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study","volume":"79","author":"Min Lee","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104002_bb0275","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/cup.13150","article-title":"Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern","volume":"45","author":"Trinidad","year":"2018","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.autrev.2026.104002_bb0280","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3389\/fimmu.2017.01547","article-title":"Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract","volume":"8","author":"Dougan","year":"2017","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104002_bb0285","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1159\/000452403","article-title":"Ipilimumab-induced enteritis without colitis: a new challenge","volume":"9","author":"Messmer","year":"2016","journal-title":"Case Rep Oncol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104002_bb0290","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Spanish group for cancer I-B. Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonzalez-Rodriguez","year":"2016","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.autrev.2026.104002_bb0295","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"de Filette","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.autrev.2026.104002_bb0300","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy","volume":"5","author":"Lee","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"10.1016\/j.autrev.2026.104002_bb0305","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1089\/thy.2016.0562","article-title":"Clinical features of nivolumab-induced thyroiditis: a case series study","volume":"27","author":"Yamauchi","year":"2017","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.autrev.2026.104002_bb0310","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/liv.13746","article-title":"Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents","volume":"38","author":"Suzman","year":"2018","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.autrev.2026.104002_bb0315","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/ijc.30678","article-title":"Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data","volume":"141","author":"Wang","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.autrev.2026.104002_bb0320","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/CMAR.S136818","article-title":"Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis","volume":"9","author":"Chuzi","year":"2017","journal-title":"Cancer Manag Res"},{"issue":"7","key":"10.1016\/j.autrev.2026.104002_bb0325","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0330","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.autrev.2026.104002_bb0335","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.autrev.2026.104002_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.autrev.2026.104002_bb0345","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","article-title":"Neurological toxicities associated with immune-checkpoint inhibitors","volume":"30","author":"Touat","year":"2017","journal-title":"Curr Opin Neurol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104002_bb0350","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti-programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0355","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11910-018-0810-1","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management","volume":"18","author":"Astaras","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"16","key":"10.1016\/j.autrev.2026.104002_bb0360","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.autrev.2026.104002_bb0365","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.autrev.2026.104002_bb0370","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s41581-022-00630-8","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury","volume":"18","author":"Sprangers","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0375","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.autrev.2026.104002_bb0380","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.autrev.2026.104002_bb0385","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-17-0358","article-title":"Endocrine side effects of cancer immunotherapy","volume":"24","author":"Cukier","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0390","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.autrev.2026.104002_bb0395","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2026.104002_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2023.102283","article-title":"Immune checkpoint receptors in autoimmunity","volume":"80","author":"Burke","year":"2023","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.autrev.2026.104002_bb0405","doi-asserted-by":"crossref","first-page":"1340373","DOI":"10.3389\/fimmu.2024.1340373","article-title":"Immune checkpoint inhibitors associated cardiovascular immune-related adverse events","volume":"15","author":"Jo","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0410","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0415","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"132","author":"Jayathilaka","year":"2025","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0420","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.autrev.2026.104002_bb0425","article-title":"Reporting of immune-related adverse events in US Food and drug administration approvals of immune checkpoint inhibitors","volume":"15\u20132025","author":"Shaili Tapiavala","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.autrev.2026.104002_bb0430","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.3332\/ecancer.2021.1314","article-title":"Defining the correlation between immune-checkpoint inhibitors-related adverse events and clinical outcomes: a narrative review","volume":"15","author":"Abdihamid","year":"2021","journal-title":"Ecancermedicalscience"},{"issue":"9","key":"10.1016\/j.autrev.2026.104002_bb0435","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.autrev.2026.104002_bb0440","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1616325","article-title":"Predicting immune-related adverse events in patients with melanoma: the role of interleukin-7 rs16906115 polymorphism and lymphocyte dynamics","volume":"16","author":"Acar","year":"2025","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104002_bb0445","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3892\/ol.2025.14957","article-title":"Incidence and management of hepatic immune-related adverse events in advanced urologic cancers treated with immune checkpoint inhibitors: a multicenter retrospective study","volume":"29","author":"Park","year":"2025","journal-title":"Oncol Lett"},{"issue":"3","key":"10.1016\/j.autrev.2026.104002_bb0450","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5415\/apallergy.0000000000000146","article-title":"From tumor to tolerance: a comprehensive review of immune checkpoint inhibitors and immune-related adverse events","volume":"14","author":"Sutanto","year":"2024","journal-title":"Asia Pac Allergy"},{"issue":"4","key":"10.1016\/j.autrev.2026.104002_bb0455","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1073\/pnas.0910341107","article-title":"Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity","volume":"107","author":"Jain","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2026.104002_bb0460","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.851032","article-title":"A systematic review of the mechanisms involved in immune checkpoint inhibitors cardiotoxicity and challenges to improve clinical safety","volume":"10","author":"Rubio-Infante","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0465","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/imr.13258","article-title":"Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: a focus on autoimmune skin toxicity and pneumonitis","volume":"318","author":"Berner","year":"2023","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0470","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/imr.13247","article-title":"Immune-related adverse events after immune check point inhibitors: understanding the intersection with autoimmunity","volume":"318","author":"Singh","year":"2023","journal-title":"Immunol Rev"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0475","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"issue":"19","key":"10.1016\/j.autrev.2026.104002_bb0480","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0485","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0490","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/L18-0209","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease","volume":"169","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0495","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"10027","key":"10.1016\/j.autrev.2026.104002_bb0500","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.autrev.2026.104002_bb0505","doi-asserted-by":"crossref","first-page":"7953","DOI":"10.3390\/curroncol29100629","article-title":"Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients","volume":"29","author":"Tong","year":"2022","journal-title":"Curr Oncol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104002_bb0510","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2105\/AJPH.90.9.1463","article-title":"Autoimmune diseases: a leading cause of death among young and middle-aged women in the United States","volume":"90","author":"Walsh","year":"2000","journal-title":"Am J Public Health"},{"issue":"3","key":"10.1016\/j.autrev.2026.104002_bb0515","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/clin.1997.4412","article-title":"Epidemiology and estimated population burden of selected autoimmune diseases in the United States","volume":"84","author":"Jacobson","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104002_bb0520","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.autrev.2006.10.001","article-title":"Gender and autoimmunity","volume":"6","author":"Zandman-Goddard","year":"2007","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0525","first-page":"99","article-title":"Epidemiology of juvenile chronic arthritis in northern Norway: a ten-year retrospective study","volume":"16","author":"Moe","year":"1998","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104002_bb0530","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/art.1780390817","article-title":"Juvenile rheumatoid arthritis in Rochester, Minnesota 1960\u20131993. Is the epidemiology changing?","volume":"39","author":"Peterson","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2026.104002_bb0535","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/00001648-199205000-00008","article-title":"Incidence of insulin-dependent diabetes mellitus in Colorado","volume":"3","author":"Kostraba","year":"1992","journal-title":"Epidemiology"},{"issue":"3","key":"10.1016\/j.autrev.2026.104002_bb0540","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/adc.77.3.210","article-title":"Rising incidence of type 1 diabetes in Scottish children, 1984\u201393. The Scottish Study Group for the Care of Young Diabetics","volume":"77","author":"Rangasami","year":"1997","journal-title":"Arch Dis Child"},{"issue":"4","key":"10.1016\/j.autrev.2026.104002_bb0545","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/art.1780400421","article-title":"Racial differences in scleroderma among women in Michigan","volume":"40","author":"Laing","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0550","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/rheumatology\/32.2.110","article-title":"The prevalence and incidence of systemic lupus erythematosus in Nottingham, UK, 1989\u20131990","volume":"32","author":"Hopkinson","year":"1993","journal-title":"Br J Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104002_bb0555","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/art.1780380415","article-title":"The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth","volume":"38","author":"Johnson","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2026.104002_bb0560","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/art.1780380914","article-title":"Incidence of systemic lupus erythematosus. Race and gender differences","volume":"38","author":"McCarty","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0565","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/1529-0131(199901)42:1<46::AID-ANR6>3.0.CO;2-2","article-title":"Trends in the incidence and mortality of systemic lupus erythematosus, 1950\u20131992","volume":"42","author":"Uramoto","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2026.104002_bb0570","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000065639","article-title":"Epidemiology of myasthenia gravis: a population-based study in Stockholm, Sweden","volume":"21","author":"Kalb","year":"2002","journal-title":"Neuroepidemiology"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0575","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1212\/WNL.56.1.62","article-title":"Prevalence and incidence of multiple sclerosis in Catania, Sicily","volume":"56","author":"Nicoletti","year":"2001","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.autrev.2026.104002_bb0580","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/jech.50.3.274","article-title":"Multiple sclerosis in south Cambridgeshire: incidence and prevalence based on a district register","volume":"50","author":"Robertson","year":"1996","journal-title":"J Epidemiol Community Health"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0585","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2265.1995.tb01894.x","article-title":"The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey","volume":"43","author":"Vanderpump","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10.1016\/j.autrev.2026.104002_bb0590","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-199905000-00001","article-title":"Influence of age on characteristics of polymyositis and dermatomyositis in adults","volume":"78","author":"Marie","year":"1999","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0595","first-page":"379","article-title":"Ethnic differences in risk for pediatric rheumatic illness in a culturally diverse population","volume":"29","author":"Kurahara","year":"2002","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104002_bb0600","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.2337\/diacare.23.10.1516","article-title":"Incidence of childhood type 1 diabetes worldwide","volume":"23","author":"Karvonen","year":"2000","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0605","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s100720170011","article-title":"The prevalence of multiple sclerosis in the world: an update","volume":"22","author":"Rosati","year":"2001","journal-title":"Neurol Sci"},{"issue":"3","key":"10.1016\/j.autrev.2026.104002_bb0610","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/art.1780400309","article-title":"Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963\u20131982","volume":"40","author":"Steen","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2026.104002_bb0615","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/rheumatology\/31.10.679","article-title":"The prevalence of diagnosed systemic lupus erythematosus in whites and Indian Asian immigrants in Leicester city, UK","volume":"31","author":"Samanta","year":"1992","journal-title":"Br J Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104002_bb0620","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/BF00265020","article-title":"Racial differences in incidence of juvenile-onset type 1 diabetes: epidemiologic studies in southern California","volume":"28","author":"Lorenzi","year":"1985","journal-title":"Diabetologia"},{"issue":"9 Pt 1","key":"10.1016\/j.autrev.2026.104002_bb0625","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1212\/WNL.29.9_Part_1.1228","article-title":"Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution","volume":"29","author":"Kurtzke","year":"1979","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.autrev.2026.104002_bb0630","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/art.10897","article-title":"Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification","volume":"48","author":"Rasch","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"7031","key":"10.1016\/j.autrev.2026.104002_bb0635","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature03479","article-title":"X-inactivation profile reveals extensive variability in X-linked gene expression in females","volume":"434","author":"Carrel","year":"2005","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.autrev.2026.104002_bb0640","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1084\/jem.20070850","article-title":"A role for sex chromosome complement in the female bias in autoimmune disease","volume":"205","author":"Smith-Bouvier","year":"2008","journal-title":"J Exp Med"},{"issue":"6942","key":"10.1016\/j.autrev.2026.104002_bb0645","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/423810a","article-title":"Tales of the Y chromosome","volume":"423","author":"Willard","year":"2003","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0650","doi-asserted-by":"crossref","DOI":"10.1186\/s40246-018-0185-z","article-title":"The X chromosome and sex-specific effects in infectious disease susceptibility","volume":"13","author":"Schurz","year":"2019","journal-title":"Hum Genomics"},{"key":"10.1016\/j.autrev.2026.104002_bb0655","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1146\/annurev.ge.17.120183.001103","article-title":"Mammalian X-chromosome inactivation","volume":"17","author":"Gartler","year":"1983","journal-title":"Annu Rev Genet"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0660","doi-asserted-by":"crossref","DOI":"10.1186\/1756-8935-1-2","article-title":"Dicer regulates Xist promoter methylation in ES cells indirectly through transcriptional control of Dnmt3a","volume":"1","author":"Nesterova","year":"2008","journal-title":"Epigenetics Chromatin"},{"issue":"8","key":"10.1016\/j.autrev.2026.104002_bb0665","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0167-5699(98)01298-5","article-title":"The female X-inactivation mosaic in systemic lupus erythematosus","volume":"19","author":"Stewart","year":"1998","journal-title":"Immunol Today"},{"issue":"7","key":"10.1016\/j.autrev.2026.104002_bb0670","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126751","article-title":"Altered X-chromosome inactivation in T cells may promote sex-biased autoimmune diseases","volume":"4","author":"Syrett","year":"2019","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0675","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ni.3643","article-title":"A gene network regulated by the transcription factor VGLL3 as a promoter of sex-biased autoimmune diseases","volume":"18","author":"Liang","year":"2017","journal-title":"Nat Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104002_bb0680","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127291","article-title":"The female-biased factor VGLL3 drives cutaneous and systemic autoimmunity","volume":"4","author":"Billi","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2026.104002_bb0685","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.brainres.2010.09.062","article-title":"Endocrine induced changes in brain function during pregnancy","volume":"1364","author":"Brunton","year":"2010","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0690","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1600-065X.2011.01002.x","article-title":"Gimme shelter: the immune system during pregnancy","volume":"241","author":"Munoz-Suano","year":"2011","journal-title":"Immunol Rev"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0695","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/ard.2009.115964","article-title":"Postpartum onset of rheumatoid arthritis and other chronic arthritides: results from a patient register linked to a medical birth registry","volume":"69","author":"Wallenius","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2026.104002_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100759","article-title":"Immune suppression in pregnancy and cancer: parallels and insights","volume":"13","author":"Kareva","year":"2020","journal-title":"Transl Oncol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104002_bb0705","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.3899\/jrheum.120269","article-title":"Pregnancy and the risk of rheumatoid arthritis in a highly predisposed North American Native population","volume":"39","author":"Peschken","year":"2012","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104002_bb0710","article-title":"The prevalence of autoimmune disorders in women: a narrative review","volume":"12","author":"Angum","year":"2020","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0715","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clim.2013.03.014","article-title":"Role of puberty in multiple sclerosis risk and course","volume":"149","author":"Chitnis","year":"2013","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2026.104002_bb0720","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00265","article-title":"Autoimmune disease in women: endocrine transition and risk across the lifespan","volume":"10","author":"Desai","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0725","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0049-0172(03)00084-2","article-title":"Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women","volume":"33","author":"Merlino","year":"2003","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0730","first-page":"11","article-title":"The role of hormones in the pathogenesis of psoriasis vulgaris","volume":"89","author":"Roman","year":"2016","journal-title":"Clujul Med"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0735","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.rdc.2016.12.011","article-title":"Menopause and rheumatic disease","volume":"43","author":"Talsania","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2026.104002_bb0740","doi-asserted-by":"crossref","DOI":"10.1186\/s13293-015-0037-7","article-title":"Sex differences in Sjogren\u2019s syndrome: a comprehensive review of immune mechanisms","volume":"6","author":"Brandt","year":"2015","journal-title":"Biol Sex Differ"},{"issue":"4","key":"10.1016\/j.autrev.2026.104002_bb0745","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3109\/s10165-012-0733-7","article-title":"Age at onset and gender distribution of systemic lupus erythematosus, polymyositis\/dermatomyositis, and systemic sclerosis in Japan","volume":"23","author":"Ohta","year":"2013","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0750","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jama.287.1.92","article-title":"Does this patient have temporal arteritis?","volume":"287","author":"Smetana","year":"2002","journal-title":"JAMA"},{"issue":"6\u20137","key":"10.1016\/j.autrev.2026.104002_bb0755","doi-asserted-by":"crossref","first-page":"A544","DOI":"10.1016\/j.autrev.2012.01.003","article-title":"Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment","volume":"11","author":"Borchers","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0760","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jaut.2009.03.005","article-title":"Female predominance and X chromosome defects in autoimmune diseases","volume":"33","author":"Invernizzi","year":"2009","journal-title":"J Autoimmun"},{"issue":"6","key":"10.1016\/j.autrev.2026.104002_bb0765","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/art.22641","article-title":"Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data","volume":"56","author":"Chakravarty","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2026.104002_bb0770","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1053\/berh.2002.0259","article-title":"Epidemiology of systemic lupus erythematosus","volume":"16","author":"Petri","year":"2002","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104002_bb0775","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1191\/0961203303lu469xx","article-title":"Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features","volume":"12","author":"Lopez","year":"2003","journal-title":"Lupus"},{"issue":"5546","key":"10.1016\/j.autrev.2026.104002_bb0780","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1126\/science.1064890","article-title":"Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus","volume":"294","author":"Blanco","year":"2001","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0785","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM197907053010102","article-title":"Immune interferon in the circulation of patients with autoimmune disease","volume":"301","author":"Hooks","year":"1979","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.autrev.2026.104002_bb0790","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.autrev.2026.104002_bb0795","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1002\/art.23619","article-title":"Age- and sex-related patterns of serum interferon-alpha activity in lupus families","volume":"58","author":"Niewold","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0800","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.bor.0000145516.45854.7b","article-title":"Microchimerism and systemic sclerosis","volume":"17","author":"Jimenez","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2026.104002_bb0805","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1749-6632.2001.tb03881.x","article-title":"From the simple detection of microchimerism in patients with autoimmune diseases to its implication in pathogenesis","volume":"945","author":"Lambert","year":"2001","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"10.1016\/j.autrev.2026.104002_bb0810","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/1529-0131(200109)44:9<2107::AID-ART361>3.0.CO;2-9","article-title":"Microchimerism in a female patient with systemic lupus erythematosus","volume":"44","author":"Johnson","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"17","key":"10.1016\/j.autrev.2026.104002_bb0815","first-page":"1653","article-title":"Giant-cell arteritis and polymyalgia rheumatica","volume":"371","author":"Weyand","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0820","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-021-00327-5","article-title":"Large-vessel vasculitis","volume":"7","author":"Pugh","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"22","key":"10.1016\/j.autrev.2026.104002_bb0825","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia Rheumatica and Giant Cell Arteritis: a systematic review","volume":"315","author":"Buttgereit","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2026.104002_bb0830","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.843305","article-title":"Aging-related vascular inflammation: giant cell arteritis and neurological disorders","volume":"14","author":"Watanabe","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"8","key":"10.1016\/j.autrev.2026.104002_bb0835","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1073\/pnas.0830997100","article-title":"Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients","volume":"100","author":"Hodi","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"10.1016\/j.autrev.2026.104002_bb0840","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma","volume":"100","author":"Phan","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.autrev.2026.104002_bb0845","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1245\/ASO.2005.03.536","article-title":"Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I\/II study","volume":"12","author":"Maker","year":"2005","journal-title":"Ann Surg Oncol"},{"issue":"15","key":"10.1016\/j.autrev.2026.104002_bb0850","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104002_bb0855","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1158\/1078-0432.CCR-06-2318","article-title":"A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer","volume":"13","author":"Small","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.autrev.2026.104002_bb0860","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J Immunother"},{"issue":"Suppl. 4","key":"10.1016\/j.autrev.2026.104002_bb0865","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.13-S4-1","article-title":"Introduction. Immune-modulating antibodies","volume":"13","author":"Weber","year":"2008","journal-title":"Oncologist"},{"issue":"25","key":"10.1016\/j.autrev.2026.104002_bb0870","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.autrev.2026.104002_bb0875","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104002_bb0880","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.autrev.2026.104002_bb0885","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.2147\/OTT.S111209","article-title":"Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment","volume":"9","author":"El-Osta","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.autrev.2026.104002_bb0890","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.09.002","article-title":"Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials","volume":"119","author":"El Osta","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0895","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/07357907.2020.1721521","article-title":"Fatal adverse events associated with pembrolizumab in cancer patients: a meta-analysis","volume":"38","author":"Sher","year":"2020","journal-title":"Cancer Invest"},{"issue":"9","key":"10.1016\/j.autrev.2026.104002_bb0900","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1007\/s12094-021-02598-6","article-title":"Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis","volume":"23","author":"Alrabadi","year":"2021","journal-title":"Clin Transl Oncol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104002_bb0905","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2145102","article-title":"Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: a meta-analysis","volume":"18","author":"Cai","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0910","article-title":"Immune checkpoint inhibitors in cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0915","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2458948","article-title":"Immune checkpoint inhibitors in cancer patients with autoimmune disease: safety and efficacy","volume":"21","author":"Le","year":"2025","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0920","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2026.104002_bb0925","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/j.seminoncol.2018.09.002","article-title":"Cancer immunotherapy-associated hypophysitis","volume":"45","author":"Solinas","year":"2018","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0930","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103698","article-title":"Artificial intelligence meets the world experts; updates and novel therapies in autoimmunity - The 14th international congress on autoimmunity 2024 (AUTO14), Ljubljana","volume":"24","author":"Mahroum","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.autrev.2026.104002_bb0935","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103166","article-title":"The mosaic of autoimmunity - Finally discussing in person. The 13(th) international congress on autoimmunity 2022 (AUTO13) Athens","volume":"21","author":"Mahroum","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104002_bb0940","series-title":"Infection and autoimmunity","author":"Mahroum","year":"2024"},{"issue":"2","key":"10.1016\/j.autrev.2026.104002_bb0945","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001550","article-title":"Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey","volume":"8","author":"Ghosh","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.autrev.2026.104002_bb0950","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Del Valle","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.autrev.2026.104002_bb0955","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/PAS.0000000000001650","article-title":"Postmortem findings associated with SARS-CoV-2: systematic review and meta-analysis","volume":"45","author":"Satturwar","year":"2021","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104002_bb0960","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.cell.2020.09.034","article-title":"Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C)","volume":"183","author":"Gruber","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.autrev.2026.104002_bb0965","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/cts.12805","article-title":"Clinical and Autoimmune characteristics of severe and critical cases of COVID-19","volume":"13","author":"Zhou","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.autrev.2026.104002_bb0970","article-title":"Predictors of severity and onset timing of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a retrospective analysis","volume":"16","author":"Fang","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104002_bb0975","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-10327-7","article-title":"Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors","volume":"22","author":"Yoshikawa","year":"2022","journal-title":"BMC Cancer"},{"issue":"17","key":"10.1016\/j.autrev.2026.104002_bb0980","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104002_bb0985","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104002_bb0990","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study","volume":"24","author":"Cortellini","year":"2019","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.autrev.2026.104002_bb0995","first-page":"7747","article-title":"Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis","volume":"29","author":"Yamaguchi","year":"2021","journal-title":"Support Care Cancer"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:13:10Z","timestamp":1788174790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226000169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":199,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1568997226000169"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104002","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmunity in the era of immune checkpoint inhibitors: the evolving epidemiology of autoimmune diseases and the possible impact of COVID-19","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104002"}}